|
Role
of Coenzyme Q10, Metformin and Rosiglitazone in Treatment of
Experimental Non Alcoholic Steatohepatitis in Rats
Mohamed A. Abd El- Hamid1,
Mahmoud S. Abd El- Halim1,
Karima I. El-Desouky2,
Heba A. Mahmoud1,
Mohamed A. Abdou1
1
Pharmacology & 2Pathology Department, Faculty of
Medicine, Tanta University, Egypt
Tanta Med. Sc. J 2008; 3(3):15-29
Article type: Original article
Background/Aim: Nonalcoholic fatty liver disease (NAFLD) includes a
wide spectrum of liver injury ranging from simple fat accumulation
in the hepatocytes (steatosis) without histological or biochemical
evidences of inflammation or fibrosis to steatohepatitis with
accumulation of fat and necroinflammatory activity. Non-alcoholic
steatohepatitis (NASH) is a metabolic liver disorder that is seen in
2-6% of the general population. The aim of the work is to study the
effect of each of Coenzyme Q10, metformin and rosiglitazone alone or
in certain combination on some parameters of mitochondrial
dysfunction in NASH, as mitochondrial ATP& MDA, hepatic TG& FFAs ,
ALT, AST, fasting blood glucose, serum insulin and HOMA-IR.
Materials & Methods: The study was carried out on 80 adult male
albino rats weighing 200-250 gram; the animals were classified into
8 groups each group contain10 rats as follow: Group1 (untreated
control group) rats were fed on normal diet 12 weeks, Group 2
received high fat diet for 12 weeks, Group 3 received high fat diet
and Coenzyme Q10, Group 4 received high fat diet and Metformin,
Group 5 received high fat diet and Rosiglitazone, Group 6 received
high fat diet and Coenzyme Q10 and Metformin, Group 7 received high
fat diet and Coenzyme Q10 and Rosiglitazone, Group 8 received high
fat diet and Coenzyme Q10, Rosiglitazone and Metformin. The
following parameters were measured: ALT, AST, fasting blood glucose,
serum insulin, HOMA- IR, mitochondrial ATP and MDA, hepatic TG and
FFAs with histopathological examination. Results: Rosiglitazone
induced significant reduction in serum transaminases, fasting blood
glucose level, fasting serum insulin, HOMA-IR, mitochondrial MDA,
hepatic TG, hepatic FFA. Metformin induced significant reduction in
serum transaminases, fasting blood glucose level, fasting serum
insulin, HOMA-IR, mitochondrial MDA, hepatic TG, hepatic FFA.
Coenzyme Q10 induced significant reduction in serum transaminases,
fasting blood glucose level, HOMA-IR, mitochondrial MDA, hepatic FFA
with significant increase in mitochondrial ATP. Conclusion: The
combination of coenzyme Q10, metformin and rosiglitazone produces
additive effect which is very important to decrease hepatic lipid
accumulation and insulin resistance which are the two main factors
in pathogenesis of NASH.
ICID 870833 |